Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00172003
First received: September 13, 2005
Last updated: August 6, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2009
  Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)